Syndax Pharmaceuticals SNDX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's additional paid-in capital?
- Syndax Pharmaceuticals (SNDX) reported additional paid-in capital of $1.59B in Q1 2026.
- How has Syndax Pharmaceuticals's additional paid-in capital changed year-over-year?
- Syndax Pharmaceuticals's additional paid-in capital increased by 4.6% year-over-year, from $1.52B to $1.59B.
- What is the long-term trend for Syndax Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's additional paid-in capital has grown at a 13.9% compound annual growth rate (CAGR), from $820.82M to $1.57B.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.